Fudan University

🇨🇳China

Country: 🇨🇳China

Ownership: Private

Established: 1905-01-01

Employees: 1K

Market Cap: -

Website: http://www.fudan.edu.cn

Clinical Trials

Comparation of Endoscopic Biopsy and Postoperative Specimen for the Molecular Diagnosis of Gastric Cancer

Conditions: Endoscopy
Pathology
Stomach Neoplasms
Biopsy

Interventions: Procedure: Surgery
Device: endoscopy

First Posted Date: 2021-03-22

Last Posted Date: 2021-12-10

Lead Sponsor: Fudan University

Target Recruit Count: 510

Registration Number: NCT04809025

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer

Phase 4

Recruiting

Conditions: Invasive Ductal Carcinoma, Breast
Carcinoma Breast
Triple-negative Breast Cancer

Interventions: Drug: Huaier Granule

First Posted Date: 2021-03-10

Last Posted Date: 2024-06-27

Lead Sponsor: Fudan University

Target Recruit Count: 1072

Registration Number: NCT04790305

Locations: 🇨🇳
Union Hospital Tongji Medical College Huazhong Univeristy of Science and Technology, Wuhan, Hubei, China
🇨🇳
The Second Affiliated Hospital of Xi'an Jiaotong University (Xibei Hospital), Xi'an, Shanxi, China
🇨🇳
The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China

and more 31 locations

mFOLFOXIRI+Bev vs. mFOLFOX6+Bev for RAS Mutant Unresectable Colorectal Liver-limited Metastases

Phase 3

Recruiting

Conditions: Colorectal Carcinoma
Liver Metastases

Interventions: Drug: mFOLFOXIRI regimen
Drug: mFOLFOX regimen
Drug: Bevacizumab

First Posted Date: 2021-03-04

Last Posted Date: 2021-09-27

Lead Sponsor: Fudan University

Target Recruit Count: 308

Registration Number: NCT04781270

Locations: 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China

Adjuvant PD-1 Antibody in Combination With Capecitabine for Patients With ICC at High-Risk of Postoperative Recurrence

Phase 1

Conditions: Cholangiocarcinoma, Intrahepatic

Interventions: Drug: Capecitabine
Drug: PD-1 Antibody（Tislelizumab）

First Posted Date: 2021-03-04

Last Posted Date: 2022-08-18

Lead Sponsor: Fudan University

Target Recruit Count: 30

Registration Number: NCT04782804

Locations: 🇨🇳
Lulu@Huashan.Org.Cn, Shanghai, China

Albumin-bound Paclitaxel Combination With Capecitabine Versus Capecitabine Monotherapy in Paclitaxel/Docetaxel-resistant Advanced Breast Cancer

Phase 2

Conditions: Breast Cancer

Interventions: Drug: Albumin-bound paclitaxel plus capecitabine
Drug: capecitabine

First Posted Date: 2021-03-03

Last Posted Date: 2021-03-03

Lead Sponsor: Fudan University

Target Recruit Count: 92

Registration Number: NCT04780347

Locations: 🇨🇳
Fudan University Shanghai Cancer center, Shanghai, China

Intraperitoneal Injection of Oncolytic Viruses H101 for Patients With Refractory Malignant Ascites

Phase 2

Completed

Conditions: Refractory Malignant Ascites

Interventions: Drug: Oncorine (H101)

First Posted Date: 2021-02-25

Last Posted Date: 2023-01-31

Lead Sponsor: Fudan University

Target Recruit Count: 25

Registration Number: NCT04771676

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

Dynamic Observational Study With PET of 68Ga-HER2-affibody in Anti-HER2 Treatment

Conditions: Breast Cancer

Interventions: Drug: Docetaxel combined with Trastuzumab±Pertuzumab
Drug: T-DM1 or Capecitabine combined with Pyrotinib regimen.

First Posted Date: 2021-02-24

Last Posted Date: 2022-04-20

Lead Sponsor: Fudan University

Target Recruit Count: 50

Registration Number: NCT04769050

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

SBRT for Oligo-residual NSCLC After Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors

Phase 2

Recruiting

Conditions: NSCLC Stage IV

Interventions: Drug: PD-1/PD-L1 inhibitors (alone or in combination with chemotherapy)
Radiation: SBRT

First Posted Date: 2021-02-23

Last Posted Date: 2025-04-30

Lead Sponsor: Fudan University

Target Recruit Count: 59

Registration Number: NCT04767009

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

Observational Prospective Study of Immune Checkpoint Inhibitors for Solid Neoplasms

Recruiting

Conditions: Cancer

First Posted Date: 2021-02-23

Last Posted Date: 2021-02-23

Lead Sponsor: Fudan University

Target Recruit Count: 1500

Registration Number: NCT04766515

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

SRT for Residual Oligometastases of NSCLC After 3rd Generation EGFR-TKIs

Phase 2

Completed

Conditions: EGFR Activating Mutation
NSCLC Stage IV

Interventions: Drug: 3rd generation EGFR-TKI
Radiation: Consolidative SRT

First Posted Date: 2021-02-21

Last Posted Date: 2024-08-19

Lead Sponsor: Fudan University

Target Recruit Count: 61

Registration Number: NCT04764214

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy